Article
Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society - 1 Sept 2022
Gramegna Andrea, De Petro Claudia, Leonardi Gloria, Contarini Martina, Amati Francesco, Meazza Roberto, Carugo Stefano, Blasi Francesco
Abstract excerpt
Elexacaftor/tezacaftor/ivacaftor (ETI) is associated with major improvements in respiratory outcomes of individuals with cystic fibrosis (CF) and at least one Phe508del mutation. Although ETI was well tolerated in registration studies, the attention on adverse events not previously described is very high in the post-marketing phase. In this case series we report the onset of systemic arterial hypertension in 4...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.